GT201300032A - Composicion farmaceutica de liberacion prolongada de trimetazidina - Google Patents

Composicion farmaceutica de liberacion prolongada de trimetazidina

Info

Publication number
GT201300032A
GT201300032A GT201300032A GT201300032A GT201300032A GT 201300032 A GT201300032 A GT 201300032A GT 201300032 A GT201300032 A GT 201300032A GT 201300032 A GT201300032 A GT 201300032A GT 201300032 A GT201300032 A GT 201300032A
Authority
GT
Guatemala
Prior art keywords
trimetazidine
prolonged
release
pharmaceutical composition
agent
Prior art date
Application number
GT201300032A
Other languages
English (en)
Inventor
Patrick Genty
Christophe Hermelin
Jean-Manuel Pean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300032A publication Critical patent/GT201300032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRITA SE REFIERE A LA MEZCLA FARMACÉUTICA PARA LA LIBERACIÓN PROLONGADA DE TRIMETAZIDINA, DONDE LA FASE INTERNA CONTIENE LA TRIMETAZIDINA Y LA CAPA EXTERIOR CONTIENE EL AGENTE DE LIBERACIÓN LENTA Y EL AGENTE ANTI-AGLOMERACIÓN.
GT201300032A 2012-02-03 2013-01-31 Composicion farmaceutica de liberacion prolongada de trimetazidina GT201300032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (1)

Publication Number Publication Date
GT201300032A true GT201300032A (es) 2014-06-09

Family

ID=47504206

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300032A GT201300032A (es) 2012-02-03 2013-01-31 Composicion farmaceutica de liberacion prolongada de trimetazidina

Country Status (47)

Country Link
US (1) US10117838B2 (es)
EP (1) EP2623096B1 (es)
JP (1) JP6338818B2 (es)
KR (2) KR20130090365A (es)
CN (2) CN103239425A (es)
AP (1) AP2013006693A0 (es)
AR (1) AR089861A1 (es)
AU (1) AU2013200481B2 (es)
BR (1) BR102013002524B1 (es)
CA (1) CA2805471C (es)
CL (1) CL2013000336A1 (es)
CO (1) CO6720159A1 (es)
CR (1) CR20130037A (es)
CU (1) CU24157B1 (es)
CY (1) CY1121696T1 (es)
DK (1) DK2623096T3 (es)
DO (1) DOP2013000024A (es)
EA (1) EA030227B1 (es)
EC (1) ECSP13012415A (es)
ES (1) ES2735053T3 (es)
FR (1) FR2986431B1 (es)
GE (1) GEP20156342B (es)
GT (1) GT201300032A (es)
HR (2) HRP20130082A2 (es)
HU (1) HUE043942T2 (es)
IL (1) IL224495B (es)
JO (1) JO3505B1 (es)
LT (1) LT2623096T (es)
MD (1) MD4622C1 (es)
MX (1) MX363302B (es)
MY (1) MY162599A (es)
NI (1) NI201300014A (es)
PE (1) PE20131119A1 (es)
PH (1) PH12013000031A1 (es)
PL (1) PL2623096T3 (es)
PT (1) PT2623096T (es)
RO (1) RO128004A3 (es)
RS (2) RS20130034A1 (es)
RU (1) RU2621128C2 (es)
SG (1) SG192386A1 (es)
SI (1) SI2623096T1 (es)
SV (1) SV2013004396A (es)
TR (1) TR201906390T4 (es)
TW (1) TWI508755B (es)
UA (1) UA118742C2 (es)
UY (1) UY34595A (es)
WO (1) WO2013114053A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163564B (zh) * 2014-04-08 2018-10-09 陶氏环球技术有限责任公司 包含酯化纤维素醚的分散体
WO2018094387A1 (en) * 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (es) * 1960-10-20
FR2490963B1 (fr) 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
EP1195160B1 (en) * 2000-10-05 2009-09-16 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
AU2002356425A1 (en) * 2001-11-21 2003-06-10 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
MX2008014059A (es) * 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
CN100571703C (zh) * 2006-12-20 2009-12-23 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
CN104739819A (zh) * 2007-11-09 2015-07-01 田边三菱制药株式会社 新型制剂
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
WO2010084397A2 (en) * 2009-01-20 2010-07-29 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (es) * 2009-01-30 2016-04-26 Lupin Limited Composiciones farmacéuticas de trimetazidina
CN102365083A (zh) * 2009-03-18 2012-02-29 赢创罗姆有限公司 采用包含聚合物混合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
EP2394644B1 (en) * 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Also Published As

Publication number Publication date
CU20130016A7 (es) 2014-10-02
CR20130037A (es) 2013-09-18
AP2013006693A0 (en) 2013-01-31
CN106924221A (zh) 2017-07-07
CL2013000336A1 (es) 2014-07-18
PL2623096T3 (pl) 2019-08-30
CO6720159A1 (es) 2013-07-31
BR102013002524B1 (pt) 2020-02-04
ECSP13012415A (es) 2014-09-30
CY1121696T1 (el) 2020-07-31
SG192386A1 (en) 2013-08-30
RS58752B1 (sr) 2019-06-28
JP6338818B2 (ja) 2018-06-06
US10117838B2 (en) 2018-11-06
EA030227B1 (ru) 2018-07-31
UY34595A (es) 2013-09-02
AR089861A1 (es) 2014-09-24
MX2013001118A (es) 2013-08-27
CU24157B1 (es) 2016-03-31
US20130202710A1 (en) 2013-08-08
TR201906390T4 (tr) 2019-05-21
DOP2013000024A (es) 2014-07-15
EP2623096A3 (fr) 2013-10-23
PH12013000031B1 (en) 2014-09-22
JP2013159609A (ja) 2013-08-19
TWI508755B (zh) 2015-11-21
ES2735053T3 (es) 2019-12-13
MX363302B (es) 2019-03-20
RU2621128C2 (ru) 2017-05-31
WO2013114053A3 (fr) 2013-12-19
LT2623096T (lt) 2019-05-10
EA201300079A3 (ru) 2013-11-29
MD4622C1 (ro) 2019-10-31
CN103239425A (zh) 2013-08-14
AU2013200481A1 (en) 2013-08-22
UA118742C2 (uk) 2019-03-11
KR20130090365A (ko) 2013-08-13
BR102013002524A2 (pt) 2014-09-09
HRP20130082A2 (hr) 2013-08-31
JO3505B1 (ar) 2020-07-05
PH12013000031A1 (en) 2014-09-22
SI2623096T1 (sl) 2019-06-28
IL224495B (en) 2020-08-31
DK2623096T3 (da) 2019-07-15
RS20130034A1 (en) 2013-10-31
PT2623096T (pt) 2019-05-30
PE20131119A1 (es) 2013-10-12
FR2986431A1 (fr) 2013-08-09
GEP20156342B (en) 2015-08-10
RO128004A3 (ro) 2013-08-30
RU2013104252A (ru) 2014-08-10
MD20130005A2 (ro) 2013-07-31
SV2013004396A (es) 2013-06-05
RO128004A0 (ro) 2012-12-28
EP2623096A2 (fr) 2013-08-07
HUE043942T2 (hu) 2019-09-30
HRP20191072T1 (hr) 2019-11-01
EA201300079A2 (ru) 2013-07-30
NI201300014A (es) 2013-05-13
NZ606550A (en) 2014-09-26
FR2986431B1 (fr) 2017-03-17
KR101918211B1 (ko) 2018-11-14
MD4622B1 (ro) 2019-03-31
TW201332591A (zh) 2013-08-16
MY162599A (en) 2017-06-30
KR20150102922A (ko) 2015-09-09
WO2013114053A2 (fr) 2013-08-08
EP2623096B1 (fr) 2019-04-03
CA2805471C (fr) 2018-05-01
CA2805471A1 (fr) 2013-08-03
AU2013200481B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
ES2694290T5 (es) Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
PE20151067A1 (es) Inhibidores de autotaxina
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
DOP2016000253A (es) Nuevos compuestos
DOP2016000039A (es) Inhibidores de rorc2 y sus usos
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
GT201500247A (es) Imidazopiridazinas sustituidas
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
UY35848A (es) Tienopirimidinas
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt